The Friedreich Ataxia drugs in development market research report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Friedreich Ataxia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued products.

GlobalData tracks 50 drugs in development for Friedreich Ataxia by 43 companies/universities/institutes. The top development phase for Friedreich Ataxia is preclinical with 25 drugs in that stage. The Friedreich Ataxia pipeline has 43 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Friedreich Ataxia pipeline products market are: Fratagene Therapeutics, Stealth BioTherapeutics and Institute for Research in Biomedicine.

The key targets in the Friedreich Ataxia pipeline products market include Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1), Kelch Like ECH Associated Protein 1 (Cytosolic Inhibitor Of Nrf2 or Inrf2 or Kelch Like Protein 19 or KEAP1), and Heat Shock Factor Protein 1 (Heat Shock Transcription Factor 1 or HSF1).

The key mechanisms of action in the Friedreich Ataxia pipeline product include Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Activator with 21 drugs in Phase II. The Friedreich Ataxia pipeline products include six routes of administration with the top ROA being Oral and seven key molecule types in the Friedreich Ataxia pipeline products market including Small Molecule, and Gene Therapy.

Friedreich Ataxia overview

Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties, and diabetes.

For a complete picture of Friedreich Ataxia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.